CO5251425A1 - Metodo y composiciones para administrar taxanos oralmente a pacientes humanos - Google Patents

Metodo y composiciones para administrar taxanos oralmente a pacientes humanos

Info

Publication number
CO5251425A1
CO5251425A1 CO00082131A CO00082131A CO5251425A1 CO 5251425 A1 CO5251425 A1 CO 5251425A1 CO 00082131 A CO00082131 A CO 00082131A CO 00082131 A CO00082131 A CO 00082131A CO 5251425 A1 CO5251425 A1 CO 5251425A1
Authority
CO
Colombia
Prior art keywords
taxane
human patients
administered
oral
orally
Prior art date
Application number
CO00082131A
Other languages
English (en)
Spanish (es)
Inventor
Samuel Brodor
Kenneth Duchin
Selim Sami
Original Assignee
Baker Norton Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baker Norton Pharma filed Critical Baker Norton Pharma
Publication of CO5251425A1 publication Critical patent/CO5251425A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CO00082131A 1999-10-27 2000-10-27 Metodo y composiciones para administrar taxanos oralmente a pacientes humanos CO5251425A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16231099P 1999-10-27 1999-10-27

Publications (1)

Publication Number Publication Date
CO5251425A1 true CO5251425A1 (es) 2003-02-28

Family

ID=22585092

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00082131A CO5251425A1 (es) 1999-10-27 2000-10-27 Metodo y composiciones para administrar taxanos oralmente a pacientes humanos

Country Status (18)

Country Link
EP (1) EP1225956A1 (ru)
JP (1) JP2003512443A (ru)
KR (1) KR20030019296A (ru)
CN (1) CN1450923A (ru)
AU (1) AU1104201A (ru)
BR (1) BR0015149A (ru)
CA (1) CA2389583A1 (ru)
CO (1) CO5251425A1 (ru)
CZ (1) CZ20021484A3 (ru)
HU (1) HUP0203303A3 (ru)
IL (1) IL149360A0 (ru)
MX (1) MXPA02004164A (ru)
NO (1) NO20022008L (ru)
PL (1) PL354777A1 (ru)
RU (1) RU2002113659A (ru)
SK (1) SK5822002A3 (ru)
WO (1) WO2001030448A1 (ru)
ZA (1) ZA200203358B (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750246B1 (en) 2000-02-03 2004-06-15 Bristol-Myers Squibb Company C-4 carbonate taxanes
JP2004536026A (ja) 2000-11-28 2004-12-02 トランスフォーム ファーマシューティカルズ，インコーポレーティッド． パクリタキセル、その誘導体、および薬剤として許容される塩を含む医薬品製剤
AU2002357012A1 (en) * 2001-11-27 2003-06-10 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
JP2006514698A (ja) * 2002-10-30 2006-05-11 スフェリックス， インコーポレイテッド ナノ粒子生物活性物質
US7345093B2 (en) 2004-04-27 2008-03-18 Formatech, Inc. Methods of enhancing solubility of compounds
US7659310B2 (en) 2004-04-27 2010-02-09 Formatech, Inc. Methods of enhancing solubility of agents
PE20060416A1 (es) * 2004-08-03 2006-06-09 Novartis Ag Composicion de inhibidores de renina e inhibidores de proteinas de efusion
CN101513395B (zh) * 2008-02-20 2011-01-12 单宝华 紫杉醇类双层软胶囊口服制剂药物
US10143652B2 (en) 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
EP2480208A1 (en) 2009-09-23 2012-08-01 Indu Javeri Methods for the preparation of liposomes
EP2566474B1 (en) 2010-05-03 2017-11-15 Teikoku Pharma USA, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
JO3737B1 (ar) * 2015-07-21 2021-01-31 Athenex Therapeutics Ltd تركيبات علاجية من باكليتاكسيل تعطى عن طريق الفم ومثبط P-gp لعلاج السرطان
EP4059497A1 (en) * 2021-03-17 2022-09-21 Dompé farmaceutici S.p.a. C5ar1 inhibitors for treating hypersensitivity reactions to taxanes
US20240180888A1 (en) * 2021-03-17 2024-06-06 Dompe' Farmaceutici Spa C5ar1 inhibitors for treating hypersensitivity reactions to taxanes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
CA2221444A1 (en) * 1996-01-31 1997-08-07 Steven B. Hansel A method of making pharmaceutically active taxanes orally bioavailable
US6025359A (en) * 1996-06-17 2000-02-15 Eli Lilly And Company Drug resistance and multidrug resistance modulators
PL337064A1 (en) * 1997-05-27 2000-07-31 Baker Norton Pharma Method of and compositions for orally administering taxanes to human beings
GB9718903D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
IL138767A0 (en) * 1998-04-01 2001-10-31 Rtp Pharma Inc Anticancer compositions
CA2371912C (en) * 1999-05-21 2010-02-16 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof

Also Published As

Publication number Publication date
BR0015149A (pt) 2002-10-29
HUP0203303A2 (hu) 2003-02-28
CN1450923A (zh) 2003-10-22
IL149360A0 (en) 2002-11-10
WO2001030448A1 (en) 2001-05-03
MXPA02004164A (es) 2002-10-17
EP1225956A1 (en) 2002-07-31
NO20022008L (no) 2002-06-19
CZ20021484A3 (cs) 2003-12-17
PL354777A1 (en) 2004-02-23
HUP0203303A3 (en) 2005-01-28
JP2003512443A (ja) 2003-04-02
CA2389583A1 (en) 2001-05-03
KR20030019296A (ko) 2003-03-06
NO20022008D0 (no) 2002-04-26
ZA200203358B (en) 2003-04-29
AU1104201A (en) 2001-05-08
RU2002113659A (ru) 2004-01-27
SK5822002A3 (en) 2003-01-09

Similar Documents

Publication Publication Date Title
CO5251425A1 (es) Metodo y composiciones para administrar taxanos oralmente a pacientes humanos
NO20014519D0 (no) Apomorfin- og sildenafilpreparat
MXPA05006940A (es) Formulaciones terapeuticas para el tratamiento de enfermedades relacionadas con beta - amiloide.
RU2007138867A (ru) Режимы дозирования транс-кломифена
RU2007119545A (ru) Пегилированный липосомальный доксорубицин в комбинации с эктеинасцидином 743 (ecteinescidin 743)
DE50203456D1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
BR9809694A (pt) Processo e composição para administração de taxanos oralmente a pacientes humanos
HK1077215A1 (en) A pharmaceutical composition for treatment of acute myocardial infarction
AR045263A1 (es) Metodo, kit y composicion farmaceutica para tratar infecciones virales
BRPI0414518A (pt) composições farmacêuticas e métodos compreendendo combinações de derivados de 2-alquilideno-19-nor-vitamina d e hormÈnio paratireoidiano
RU2005131578A (ru) Аплидин для лечения множественной миеломы
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
PT1251850E (pt) Utilizacao de uma preparacao de combinacao na terapia do cancro
WO2001080895A3 (en) Methods and compositions for the treatment of cardiac indications
CA2368352A1 (en) Method for treating neurodegeneration
TW200501967A (en) Nemorubicin for use in the preparation of a medicament for liver disease
NZ516026A (en) Oral administration of taxanes to human patients using cyclosporins as bioavailability-enhancing agents
Susman Relapsed Mantle Cell Lymphoma: Thalidomide Adds to Rituximab's Potency
RU2002113978A (ru) Способ стимуляции моторной активности кишечника
DK1265629T3 (da) Anvendelse af væksthormon i lav dosis
RU2006138043A (ru) Способ лечения инсульта с применением введения дефибриногенизирующих средств для достижения специфического характера дефибриногенизации
Kamimura et al. Drug therapy for depression in Japan
TH54155B (th) วิธีการรักษาอาการประสาทเสื่อม
AR043241A1 (es) Terapia combinada que comprende un derivado de indolpirrol-carbazol y otro agente antitumoral

Legal Events

Date Code Title Description
FC Application refused